Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) is a pioneering biotechnology company that focuses on discovering, developing, and commercializing novel gene and cell therapies, as well as vaccines aimed at improving health and offering hope to patients worldwide. The company's innovative efforts are concentrated on addressing rare and underserved ocular disorders.
Ocugen's core business revolves around a robust clinical pipeline which includes:
- OCU400: A groundbreaking gene-agnostic modifier gene therapy for retinitis pigmentosa (RP), currently in Phase 3 clinical trials. It leverages the nuclear hormone receptor gene NR2E3 to reset altered cellular gene networks and improve retinal health.
- OCU410: A potential one-time gene therapy for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). This therapy targets multiple pathways involved in the disease, including lipid metabolism, inflammation, oxidative stress, and the complement system.
- OCU410ST: Another modifier gene therapy in Phase 1/2 clinical trials for Stargardt disease, the most common form of inherited macular degeneration. It utilizes the AAV delivery platform for the RORA gene to regulate pathways linked to the disease.
Recent milestones include positive feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the OCU400 Phase 3 liMeliGhT clinical trial, as well as the inclusion of Ocugen in the Russell 3000® Index, highlighting its market presence and growth potential.
Ocugen's commitment to innovative therapies is evident through its modifier gene therapy platforms designed to fulfill unmet medical needs related to inherited retinal diseases such as RP, Leber congenital amaurosis, and Stargardt disease. Additionally, the company is advancing research in infectious diseases to bolster public health and orthopedic diseases to meet unmet medical needs.
For the latest updates and detailed information about Ocugen, Inc., visit their official website at www.ocugen.com and follow them on X and LinkedIn.
Ocugen, a biotechnology company, announces its in-person Research & Development (R&D) Day on November 1, 2022, at the Nasdaq Market Site in New York City. The event aims to showcase Ocugen's innovative gene therapy and vaccine technologies, with panel discussions featuring leading experts such as Neena B. Haider, Mark Pennesi, and David Fajgenbaum. Attendees will gain insights into Ocugen's pipeline and business strategies. Registration is required, and a webcast replay will be available within 48 hours post-event.
Ocugen, Inc. (NASDAQ: OCGN) announced that the Independent Data and Safety Monitoring Board completed a review of the safety data for its OCU400 Phase 1/2 clinical trial and recommends proceeding to enroll subjects in Cohort 3. No safety concerns were noted in the ongoing trial, which focuses on treating inherited retinal degeneration. The company expects to complete Cohort 3 enrollment by Q4 2022. OCU400 aims to address unmet needs in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations.
Ocugen, a biotechnology firm (NASDAQ: OCGN), announced participation in two key conferences on October 12, 2022. Dr. Shankar Musunuri will present their Modifier Gene Therapy platform for inherited retinal diseases at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA, while Dr. Robert J. Hopkins will discuss COVAXIN™, a COVID-19 vaccine candidate in Phase 2/3 trials, at the Vaccines Summit in Reston, VA. The company emphasizes its commitment to innovative gene and cell therapies aimed at improving global health.
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri, CEO and Co-Founder, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 4, 2022. The event takes place at the Westin Grand Central Hotel in New York City, from 8:30 to 8:55 a.m. ET. A live webcast will be available for viewers. Ocugen focuses on developing innovative gene and cell therapies, aiming to improve health and address unmet medical needs globally. For more details, visit their website.
Ocugen announced on Sept. 16, 2022, that its Compensation Committee approved stock options and restricted stock units (RSUs) for five new hires, totaling 148,800 shares in stock options and 40,092 shares in RSUs. The options, granted at an exercise price of $2.17, have a ten-year term and vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. Ocugen focuses on novel gene and cell therapies and vaccines, aiming to improve health and address unmet medical needs.
Ocugen, Inc. announced the publication of a comprehensive review on BBV152, commercialized as COVAXIN™, highlighting its effectiveness against COVID-19 and its variants, particularly Delta and Omicron. The review published in Frontiers in Immunology emphasizes the vaccine's immunogenicity, safety, and efficacy. BBV152 shows 77.8% protection from symptomatic COVID-19 and over 95% seroconversion in pediatric populations. COVAXIN™ has been authorized in 28 countries and accepted by over 85 for travel, enhancing its global accessibility. The company is investigating its use in adults in the U.S.
Ocugen, a biotechnology company, announces that Chief Scientific Officer Arun Upadhyay will speak at the 3rd Annual Gene Therapy for Ophthalmic Disorders Conference from September 13-16 in Danvers, Massachusetts. Dr. Upadhyay's presentation, scheduled for September 14 at 9:15 a.m. ET, will focus on the Modifier Gene Therapy Approach for Retinitis Pigmentosa. This event highlights Ocugen's commitment to advancing innovative therapies for retinal diseases. The company is actively developing gene and cell therapies to improve patient outcomes globally.
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. The chat is scheduled for September 12, 2022, from 3:30 – 4:00 p.m. ET at the Lotte New York Palace Hotel. A live video webcast will be available on the Ocugen investor site at the time of the event, with a replay archived for 90 days. Ocugen focuses on innovative gene and cell therapies and vaccines.
Ocugen, Inc. (NASDAQ: OCGN) announced the appointment of Robert J. Hopkins as Chief Medical Officer and Arun Upadhyay as Chief Scientific Officer. Dr. Hopkins brings over 25 years of experience in clinical research and has previously served as Chief Medical Officer at Adaptive Phage Therapeutics. Dr. Upadhyay transitions from Senior Vice President to lead the company’s R&D efforts. The leadership changes aim to enhance Ocugen's clinical programs and product development in gene therapies and vaccines, particularly for COVID-19 and retinal diseases.
FAQ
What is the current stock price of Ocugen (OCGN)?
What is the market cap of Ocugen (OCGN)?
What does Ocugen, Inc. specialize in?
What are Ocugen's key projects?
What recent achievements has Ocugen accomplished?
How does OCU400 work?
What is the significance of Ocugen's modifier gene therapy platform?
What are the target conditions for OCU410?
How does OCU410ST aim to treat Stargardt disease?
What is the impact of Ocugen's inclusion in the Russell 3000® Index?
What steps has Ocugen taken to ensure the success of its clinical therapy programs?
Where can I learn more about Ocugen's latest news and developments?
